Vericel
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 314
- Market Cap
- $2.6B
- Introduction
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
Clinical Trials
16
Trial Phases
4 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
- Conditions
- Chondral DefectArticular Cartilage Defect
- Interventions
- Procedure: Bone Marrow Stimulation
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Vericel Corporation
- Target Recruit Count
- 276
- Registration Number
- NCT06915233
A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
- Conditions
- Chondral DefectArticular Cartilage DefectOsteochondritis Dissecans (OCD)Articular Cartilage Disorder of Knee
- Interventions
- Procedure: microfracture
- First Posted Date
- 2018-07-17
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Vericel Corporation
- Target Recruit Count
- 45
- Registration Number
- NCT03588975
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸Shriner's Hospital for Children Northern California, Sacramento, California, United States
🇺🇸University of California Davis Health, Sacramento, California, United States
An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)
- Conditions
- Ischemic Dilated Cardiomyopathy (IDCM)
- First Posted Date
- 2012-08-23
- Last Posted Date
- 2021-05-27
- Lead Sponsor
- Vericel Corporation
- Target Recruit Count
- 114
- Registration Number
- NCT01670981
- Locations
- 🇺🇸
Cardiology, P.C. & Center for Therapeutic Angiogenesis, Birmingham, Alabama, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Mercy Gilbert Medical Center, Gilbert, Arizona, United States
An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)
- Conditions
- Critical Limb Ischemia
- First Posted Date
- 2011-12-02
- Last Posted Date
- 2021-05-27
- Lead Sponsor
- Vericel Corporation
- Target Recruit Count
- 41
- Registration Number
- NCT01483898
- Locations
- 🇺🇸
Cardiology PC, Birmingham, Alabama, United States
🇺🇸Cardio-Thoracic Surgeons, P.C., Birmingham, Alabama, United States
🇺🇸University Of Alabama At Birmingham, Birmingham, Alabama, United States
Extension Study for Participants of MACI00206 Study of MACI® for the Treatment of Symptomatic Articular Cartilage Defects of the Knee
- Conditions
- Articular Cartilage Defects
- First Posted Date
- 2010-12-02
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- Vericel Corporation
- Target Recruit Count
- 128
- Registration Number
- NCT01251588
- Locations
- 🇨🇿
Urazova nemocnice v Brne, Brno, Czechia
🇨🇿University Hospital Na Bulovce- Department of Orthopaedic Surgery Postgraduate Medical Institute, Praha 8, Czechia
🇫🇷Polyclinique Saint-Roch, Montpellier Cedex 2, France
- Prev
- 1
- 2
- 3
- Next
News
FDA Approves Arthroscopic Delivery for MACI Knee Cartilage Repair
The FDA has approved a supplemental Biologics License Application for arthroscopic delivery of MACI, an autologous cultured chondrocytes on a porcine collagen membrane, for knee cartilage repair.
FDA Approves NexoBrid for Pediatric Thermal Burn Treatment
The FDA has approved NexoBrid (anacaulase-bcdb) for eschar removal in pediatric patients with deep partial-thickness and full-thickness thermal burns.